We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 16, 2022

Avelumab in Unresectable/Metastatic, Progressive, Grade 2–3 Neuroendocrine Neoplasms

European Journal of Cancer

 

Additional Info

European Journal of Cancer
Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials
Eur. J. Cancer 2022 Jul 01;169(xx)74-81, DL Chan, V Rodriguez-Freixinos, M Doherty, K Wasson, N Iscoe, W Raskin, J Hallet, S Myrehaug, C Law, A Thawer, K Nguyen, S Singh

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading